top of page

Empowering Clinicians. Supporting Patients.

GeneFirst are dedicated to empowering healthcare professionals with unique technical innovations designed to overcome limitations of traditional testing solutions.

With a commitment to excellence and a focus on supporting patient outcomes, we strive to be your trusted partner in clinical decision-making.
 
Explore our offerings and discover how we can support your healthcare needs. Our portfolio spans oncology, women's health, and respiratory infections.

Genefirst Website News picture NGS_edite

Oncology

Oncology

Oncology

GeneFirst has developed oncology solutions to support clinical decision making which specifically address hurdles with processing challenging clinical samples.

These include solutions based on proprietary next-generation sequencing DNA capture chemistry (ATOM-Seq), and on MMD, a qPCR-based high-throughput, single-target mutation detection assay.

ATOM-Seq

A reimagining of how to process patient samples. They are designed to address the challenges of processing limited or poor-quality clinical samples, whilst also achieving the highest quality and sensitivity to provide ultimate confidence in test results.

Cell-free DNA

Assays designed to maximise the capture of all cell-free DNA, ensuring even the lowest frequency mutation is found.

Targeted cfDNA Enrichment

Total cfDNA Capture

FFPE DNA

Assays designed to capture FFPE DNA, allowing even the lowest quality samples to be successfully processed.

FFPE RNA

Assays designed to capture FFPE RNA and enrich conserved fusion partners to detect and identify every fusion.

MMD

Using specially designed mutation-specific primers to amplify only DNA that contains targeted mutations. This allows very high sensitivity, making MMD-PCR technology particularly suited for detecting cancerous mutations at very low frequencies.

JAK2

Mutation Test Kit enables detection of V617F mutation in jak2 gene.

ABL

Mutation Test Kit enables detection of T315I mutation in ABL gene.

Women's Health

Women's Health

 To support HPV screening and cervical cancer detection programs, GeneFirst has developed unique HPV-DNA and HPV-RNA solutions based on a novel 
high-throughput multiplexing qPCR technology known as MPA.

MPA

Overcomes the limitation of real-time PCR multiplexing by allowing differentiation of up to six different targets per fluorescence channel through the use of differential high-resolution melt curve analysis.

HR-HPV DNA

Simultaneous detection and differentiation of all high-risk HPV types including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.

HR-HPV mRNA 

Designed to complement the HR-HPV DNA kit by detecting E6/E7 mRNA to identify risk of cervical cancer in HPV positive individuals 

Respiratory

Respiratory Infections

 To support detection of pathogens infecting the upper and lower airways which are responsible for diseases including pneumonia, GeneFirst has developed two solutions based on a unique, high-throughput multiplexing qPCR technology (MPA).

Lower Airway

An accurate and sensitive multiplex PCR test for the detection of 9 pathogens associated with community-acquired pneumonia

Upper Airway

An accurate and sensitive multiplex PCR test for the detection of 11 pathogens commonly found in the upper respiratory tract

News and Resources

bottom of page